These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
111 related items for PubMed ID: 728892
41. Levamisole augmentation of lymphocyte hyporesponsiveness to phytohaemagglutinin in patients with pulmonary tuberculosis. Chan SH, Lee SK, Simons MJ, Stanley NF. Proc Soc Exp Biol Med; 1976 Apr; 151(4):716-9. PubMed ID: 1265056 [Abstract] [Full Text] [Related]
42. Splenic alterations during mammary tumorigenesis: diverse effects on different immune parameters. Paul RD, Ghaffar A, Sigel MM, Charyulu V, Lopez DM. Anticancer Res; 1981 Apr; 1(2):63-9. PubMed ID: 6214206 [Abstract] [Full Text] [Related]
43. Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease-nonobese diabetic mice: relation with interleukin-10 induction. Asselin-Paturel C, Megherat S, Vergnon I, Echchakir H, Dorothée G, Blesson S, Gay F, Mami-Chouaib F, Chouaib S. Cancer; 2001 Jan 01; 91(1):113-22. PubMed ID: 11148567 [Abstract] [Full Text] [Related]
44. Associated effects of bromocriptine on neoplastic progression of mouse mammary preneoplastic hyperplastic alveolar nodule line C4 and on hyperplastic alveolar nodule-infiltrating and splenic lymphocyte function. Tsai SJ, Loeffler DA, Heppner GH. Cancer Res; 1992 Apr 15; 52(8):2209-15. PubMed ID: 1559224 [Abstract] [Full Text] [Related]
45. Effect of levamisole on immune function and reproductive performance in first-litter gilts. Purswell BJ, Dawe DL, Brown J, Williams DJ. Am J Vet Res; 1988 Jun 15; 49(6):856-9. PubMed ID: 3400922 [Abstract] [Full Text] [Related]
46. Effects of Bacillus Calmette-Guérin and levamisole on immune responses in young adult and age-immunodepressed mice. Bruley-Rosset M, Florentin I, Kiger N, Davigny M, Mathé G. Cancer Treat Rep; 1978 Nov 15; 62(11):1641-50. PubMed ID: 728893 [Abstract] [Full Text] [Related]
47. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE. Anticancer Res; 2001 Nov 15; 21(5):3425-32. PubMed ID: 11848504 [Abstract] [Full Text] [Related]
48. Effect of levamisole on the lymphocyte and macrophage activity in carp (Cyprinus carpio). Siwicki AK, Cossarini-Dunier M. Ann Rech Vet; 1990 Nov 15; 21(2):95-100. PubMed ID: 2360777 [Abstract] [Full Text] [Related]
49. Lymphocytes T and pharmacokinetics after a single oral dose of levamisole in healthy and cancer subjects. Luyckx M, Cazin M, Brunet C, Cazin JC, Devulder B, Gosselin P, Adenis L, Cappelaere P, Granier AM, Demaille A. Methods Find Exp Clin Pharmacol; 1983 Sep 15; 5(7):467-9. PubMed ID: 6608036 [Abstract] [Full Text] [Related]
50. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A. Clin Cancer Res; 2009 Jan 01; 15(1):110-8. PubMed ID: 19118038 [Abstract] [Full Text] [Related]
51. Effect of levamisole on cell-mediated immune responses in patients with nasopharyngeal carcinoma. Goh EH, Chan SH, Simons MJ. IARC Sci Publ (1971); 1978 Jan 01; (20):503-10. PubMed ID: 730200 [Abstract] [Full Text] [Related]
52. Nonspecific mitogen responses of peripheral lymphocytes in levamisole-treated patients with herpetic stromal keratitis. Sakata H, Hiyama N, Kondo H, Hirakawa Y, Yoshida H. Hiroshima J Med Sci; 1984 Dec 01; 33(4):813-7. PubMed ID: 6534935 [No Abstract] [Full Text] [Related]
53. Isoprinosine and levamisole immunomodulation in artificially reared neonatal pigs. Hennessy KJ, Blecha F, Pollmann DS, Kluber EF. Am J Vet Res; 1987 Mar 01; 48(3):477-80. PubMed ID: 2436512 [Abstract] [Full Text] [Related]
54. Effect of levamisole (NSC-177023) on in vitro human lymphocyte transformation. Copeland D, Stewart T, Harris J. Cancer Chemother Rep; 1974 Mar 01; 58(2):167-70. PubMed ID: 4830496 [No Abstract] [Full Text] [Related]
55. II. In vitro restoration by levamisole of mitogen responsiveness in zinc-deprived rats. Gross RL, Osdin N, Fong L, Newberne PM. Am J Clin Nutr; 1979 Jun 01; 32(6):1267-71. PubMed ID: 443189 [Abstract] [Full Text] [Related]
56. Concentrations of levamisole required for enhanced proliferation of human lymphocytes and phagocytosis by macrophages. Al-Ibrahim MS, Holzman RS, Lawrence HS. J Infect Dis; 1977 Apr 01; 135(4):517-23. PubMed ID: 853245 [Abstract] [Full Text] [Related]
57. [Levamisole as an immunoregulatory drug]. Górska M. Pol Tyg Lek; 1979 Apr 02; 34(14):553-5. PubMed ID: 377261 [No Abstract] [Full Text] [Related]
58. Immunotherapy with levamisole: early decrease of cAMP levels in lymphocytes from treated cancer patients. Lewinski UH, Mavligit GM, Thompson WJ, Hersh EM, Ortez RA. Cancer; 1979 Oct 02; 44(4):1280-3. PubMed ID: 227560 [Abstract] [Full Text] [Related]
59. Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. Stevenson HC, Green I, Hamilton JM, Calabro BA, Parkinson DR. J Clin Oncol; 1991 Nov 02; 9(11):2052-66. PubMed ID: 1941064 [Abstract] [Full Text] [Related]
60. Cellular immune modulation after a single high dose of Levamisole in patients with carcinoma. Lewinski UH, Mavligit GM, Hersh EM. Cancer; 1980 Nov 15; 46(10):2185-94. PubMed ID: 7427861 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]